ArticleActas espanolas de psiquiatria2025
A Multi-Label Deep Learning Model for Detailed Classification of Alzheimer's Disease.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- Machine learning-driven multi-omics integration of urinary organic acids and ions enables precision risk stratification for calcium oxalate nephrolithiasis.Frontiers in medicine · 2026Article
- Revolutionizing Alzheimer's disease detection with a cutting-edge CAPCBAM deep learning framework.Scientific reports · 2025Article
- Harnessing artificial intelligence for brain disease: advances in diagnosis, drug discovery, and closed-loop therapeutics.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate diagnosis and classification of Alzheimer's disease (AD) are crucial for effective treatment and management. Traditional diagnostic models, largely based on binary classification systems, fail to adequately capture the complexities and variations across different stages and subtypes of AD, limiting their clinical utility.
methodsWe developed a deep learning model integrating a dot-product attention mechanism and an innovative labeling system to enhance the diagnosis and classification of AD subtypes and severity levels. This model processed various clinical and demographic data, emphasizing the most relevant features for AD diagnosis. The approach emphasized precision in identifying disease subtypes and predicting their severity through advanced computational techniques that mimic expert clinical decision-making.
resultsComparative tests against a baseline fully connected neural network demonstrated that our proposed model significantly improved diagnostic accuracy. Our model achieved an accuracy of 83.1% for identifying AD subtypes, compared to 72.9% by the baseline. In severity prediction, our model reached an accuracy of 83.3%, outperforming the baseline (73.5%).
conclusionsThe incorporation of a dot-product attention mechanism and a tailored labeling system in our model significantly enhances the accuracy of diagnosing and classifying AD. This improvement highlights the potential of the model to support personalized treatment strategies and advance precision medicine in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.